title: The emergence of non-secretory multiple myeloma during the non-cytotoxic treatment of essential thrombocythemia: a case report.
abstract: BACKGROUND
  The emergence of multiple myeloma as a second malignancy in patients with essential thrombocythemia is extremely rare. Several cases have been published so far, pointing out the impact of a cytotoxic effect during treatment of essential thrombocythemia on the development of multiple myeloma.
  
  
  METHODS
  We report the case of a 52-year-old Caucasian man who presented to our hospital because of leukocytosis, a slightly decreased hemoglobin level and thrombocytosis. After a complete hematological work-up, essential thrombocythemia was diagnosed. The patient was included in a multicenter clinical study, treated with anagrelide and his platelet counts were maintained in the normal range for more than 3 years. A sudden drop in his hemoglobin level with normal leukocyte and platelet count occurred at the same time as a back pain. Magnetic resonance imaging of his spine revealed the existence of a pathological fracture of Th4, the collapse of the upper edge of Th7 and osteolytic lesions of multiple thoracic vertebrae. Repeated hematological examinations, including bone biopsy with immunohistochemistry, disclosed diagnosis of multiple myeloma of the non-secretory type.
  
  
  CONCLUSIONS
  To the best of our knowledge this is the first published case in which multiple myeloma developed during the treatment of essential thrombocythemia with the non-cytotoxic drug anagrelide. Our attempts to find a common origin for the coexistence of multiple myeloma and essential thrombocythemia have not confirmed the genetic basis of their appearance. Further studies are needed to determine the biological impact of this coexistence.
authors.forename: Danijela
authors.initials: D
authors.lastname: Leković
authors.forename: Mirjana
authors.initials: M
authors.lastname: Gotić
authors.forename: Olivera
authors.initials: O
authors.lastname: Mitrović
authors.forename: Milica
authors.initials: M
authors.lastname: Radojković
authors.forename: Jelena
authors.initials: J
authors.lastname: Bila
authors.forename: Marija
authors.initials: M
authors.lastname: Dencic-Fekete
authors.forename: Nada
authors.initials: N
authors.lastname: Kraguljac-Kurtović
authors.forename: Maja
authors.initials: M
authors.lastname: Peruničić-Jovanović
authors.forename: Vladan
authors.initials: V
authors.lastname: Cokić
references.citation: Hematology. 2008 Aug;13(4):195-202
references.pmid: 18796244
references.citation: Pathologica. 2010 Jun;102(3):83-7
references.pmid: 21171509
references.citation: Cancer. 2004 Nov 15;101(10):2239-46
references.pmid: 15476273
references.citation: Haematologica. 2003 Apr;88(4):ECR09
references.pmid: 12681982
references.citation: Leuk Res. 2005 May;29(5):481-91
references.pmid: 15755500
references.citation: Leuk Lymphoma. 2004 Apr;45(4):821-4
references.pmid: 15160964
references.citation: Br J Haematol. 2000 Sep;110(3):577-83
references.pmid: 10997967
references.citation: Clin Lymphoma Myeloma Leuk. 2011 Oct;11(5):442-5
references.pmid: 21859555
references.citation: Blood Cells Mol Dis. 2012 Oct 15-Dec 15;49(3-4):170-6
references.pmid: 22818858
references.citation: Haematologica. 2003 Oct;88(10):1130-8
references.pmid: 14555309
references.citation: Acta Haematol. 2008;120(3):177-81
references.pmid: 19129688
references.citation: Blood. 2013 Mar 7;121(10):1720-8
references.pmid: 23315161
references.citation: J Clin Oncol. 2011 Jun 10;29(17):2410-5
references.pmid: 21537037
references.citation: Blood. 2004 Aug 1;104(3):829-31
references.pmid: 15090444
references.citation: Am J Clin Pathol. 2004 Apr;121(4):482-8
references.pmid: 15080299
references.citation: Leuk Lymphoma. 2010 Sep;51(9):1727-33
references.pmid: 20615083
references.citation: Anticancer Res. 2010 Jul;30(7):2831-6
references.pmid: 20683019